Natriuretic Peptide Plasma Concentrations and Risk of Cardiovascular Versus Non-Cardiovascular Events in Heart Failure with Reduced Ejection Fraction Insights from the PARADIGM-HF and ATMOSPHERE Trials.

[1]  P. Ponikowski,et al.  Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction. , 2020, The New England journal of medicine.

[2]  S. Solomon,et al.  Natriuretic Peptides as Biomarkers of Treatment Response in Clinical Trials of Heart Failure. , 2018, JACC. Heart failure.

[3]  J. Januzzi.  Will Biomarkers Succeed as a Surrogate Endpoint in Heart Failure Trials? , 2018, JACC. Heart failure.

[4]  Akshay S. Desai,et al.  Prognostic Value of N-Terminal Pro-B-Type Natriuretic Peptide Levels in Heart Failure Patients With and Without Atrial Fibrillation , 2017, Circulation. Heart failure.

[5]  D. DeMets,et al.  Long-Term Effects of Flosequinan on the Morbidity and Mortality of Patients With Severe Chronic Heart Failure: Primary Results of the PROFILE Trial After 24 Years. , 2017, JACC. Heart failure.

[6]  Akshay S. Desai,et al.  Prognostic Implications of Changes in N-Terminal Pro-B-Type Natriuretic Peptide in Patients With Heart Failure. , 2016, Journal of the American College of Cardiology.

[7]  B. Cauliez,et al.  Clinical Value of Natriuretic Peptides in Predicting Time to Dialysis in Stage 4 and 5 Chronic Kidney Disease Patients , 2016, PloS one.

[8]  Akshay S. Desai,et al.  Aliskiren, Enalapril, or Aliskiren and Enalapril in Heart Failure. , 2016, The New England journal of medicine.

[9]  Katharina Dworzynski,et al.  The diagnostic accuracy of the natriuretic peptides in heart failure: systematic review and diagnostic meta-analysis in the acute care setting , 2015, BMJ : British Medical Journal.

[10]  Akshay S. Desai,et al.  Angiotensin-neprilysin inhibition versus enalapril in heart failure. , 2014, The New England journal of medicine.

[11]  Akshay S. Desai,et al.  Baseline characteristics and treatment of patients in Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure trial (PARADIGM-HF) , 2014, European journal of heart failure.

[12]  Satoshi Okayama,et al.  Prognostic value of B-type natriuretic peptide and its amino-terminal proBNP fragment for cardiovascular events with stratification by renal function. , 2013, Journal of cardiology.

[13]  Henry Krum,et al.  Direct renin inhibition in addition to or as an alternative to angiotensin converting enzyme inhibition in patients with chronic systolic heart failure: rationale and design of the Aliskiren Trial to Minimize OutcomeS in Patients with HEart failuRE (ATMOSPHERE) study , 2011, European journal of heart failure.

[14]  L. Tavazzi,et al.  The predictive value of stable precursor fragments of vasoactive peptides in patients with chronic heart failure: data from the GISSI‐heart failure (GISSI‐HF) trial , 2010, European journal of heart failure.

[15]  G. Giannakoulas,et al.  Elevated brain natriuretic peptide predicts mortality in interstitial lung disease , 2010, European Respiratory Journal.

[16]  Wojciech Zareba,et al.  Cardiac-resynchronization therapy for the prevention of heart-failure events. , 2009, The New England journal of medicine.

[17]  J. Cleland,et al.  The prognostic value of repeated measurement of N‐terminal pro‐B‐type natriuretic peptide in patients with chronic heart failure due to left ventricular systolic dysfunction , 2009, European journal of heart failure.

[18]  J. Daubert,et al.  Cardiac resynchronization therapy: are modern myths preventing appropriate use? , 2009, Journal of the American College of Cardiology.

[19]  Gianni Tognoni,et al.  Prognostic value of changes in N-terminal pro-brain natriuretic peptide in Val-HeFT (Valsartan Heart Failure Trial). , 2008, Journal of the American College of Cardiology.

[20]  W Frank Peacock,et al.  State of the art: Using natriuretic peptide levels in clinical practice , 2008, European journal of heart failure.

[21]  T. McDonagh,et al.  A change in N‐terminal pro‐brain natriuretic peptide is predictive of outcome in patients with advanced heart failure , 2007, European journal of heart failure.

[22]  R. Fitzgerald,et al.  Correlation and prognostic utility of B-type natriuretic peptide and its amino-terminal fragment in patients with chronic kidney disease. , 2006, American journal of clinical pathology.

[23]  J. Behr,et al.  Brain natriuretic peptide is a prognostic parameter in chronic lung disease. , 2006, American journal of respiratory and critical care medicine.

[24]  J. Cohn,et al.  Incremental prognostic value of changes in B-type natriuretic peptide in heart failure. , 2006, The American journal of medicine.

[25]  M. Vogeser,et al.  Clinical significance of brain natriuretic peptide in primary pulmonary hypertension. , 2004, Journal of the American College of Cardiology.

[26]  Hugo A Katus,et al.  NT‐proBNP in severe chronic heart failure: rationale, design and preliminary results of the COPERNICUS NT‐proBNP substudy , 2004, European journal of heart failure.

[27]  M. Kinoshita,et al.  Effect of spironolactone on plasma brain natriuretic peptide and left ventricular remodeling in patients with congestive heart failure. , 2001, Journal of the American College of Cardiology.